Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GLSI
GLSI logo

GLSI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Greenwich Lifesciences Inc (GLSI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
18.570
1 Day change
-9.15%
52 Week Range
34.100
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

GLSI is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has no strong proprietary buy signal, no supportive news catalyst, neutral insider and hedge fund activity, and weak near-term trend expectations. Based on the current data, I would not buy it now.

Technical Analysis

Price is 22.1, only slightly above the prior close of 22, while the regular session showed a sharp -7.17% move, indicating weakness despite the flat close. RSI_6 at 45.84 is neutral, MACD histogram is positive but contracting, and moving averages are converging, which points to a lack of strong momentum. The pivot at 21.214 is just below the current price, with resistance at 24.415 and 26.393 and support at 18.013 and 16.035. Overall trend is mixed to weak, with no clear bullish breakout setup.

Positive Catalysts

  • No news in the recent week. There are no significant positive trading trends from hedge funds or insiders, and no AI Stock Picker or SwingMax buy signal today. The stock is near support and could stabilize, but there is no confirmed catalyst.

Neutral/Negative Catalysts

  • Recent regular-market price change was -7.17%, showing immediate selling pressure. Similar-pattern analysis suggests a 50% chance of -3.08% next day, -1.03% next week, and -3.39% next month. Hedge funds and insiders are neutral, there is no recent news catalyst, and no congress trading data is available. There is also no valuation data or financial snapshot to support a stronger thesis.

Financial Performance

Financial snapshot data is unavailable due to an error, so latest quarter revenue, earnings, and growth trends cannot be assessed. The latest quarter season is not provided.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of improving Wall Street sentiment or rising price targets. Based on the available data, pros would likely cite the absence of major negative insider/hedge fund activity, while cons would focus on weak recent price action, no news catalyst, and no proprietary buy signal.

Wall Street analysts forecast GLSI stock price to rise
2 Analyst Rating
Wall Street analysts forecast GLSI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.440
sliders
Low
45
Averages
47.5
High
50
Current: 20.440
sliders
Low
45
Averages
47.5
High
50
H.C. Wainwright
Buy
upgrade
$39 -> $50
AI Analysis
2025-12-30
Reason
H.C. Wainwright
Price Target
$39 -> $50
AI Analysis
2025-12-30
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Greenwich LifeSciences to $50 from $39 and keeps a Buy rating on the shares. The firm cites the positive efficacy in the non-HLA-A*02 arm of the ongoing Phase 3 FLAMINGO-01 trial of GLSI-100 in breast cancer for the target boost. GLSI-100 reduced breast cancer recurrence by 80% in the non- HLA-A*02 arm, the analyst tells investors in a research note. H.C. Wainwright views the preliminary data as "highly encouraging," saying it could double the market for GLSI-100.
Noble Capital
Outperform
initiated
$45
2025-08-20
Reason
Noble Capital
Price Target
$45
2025-08-20
initiated
Outperform
Reason
Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees \"large market potential\" for GLSI-100.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GLSI
Unlock Now

People Also Watch